Member Info for ogm4

1.80p now

For one second I thought there was an RNS out...

Https://x.com/genedriveplc/status/1809239657726595530

Great find SPQStrader!...

Looks like the share price is gaining some traction now...

The good thing is GDR is not a one-trick pony and the CYP2C19 market is huge really.

As they say prevention is better than cure, so curious to see which new contracts are in the pipeline the coming months.

I'm wondering whether the NHS will see a major restructure after the elections

Remember the total addressable global market for CYP2C19 is estimated worth around £220 Million GBP with 12 million strokes annually, that's a big market!...

"Our CYP2C19 test is the only one we are aware of that can deliver clinically actionable results for these DNA variants in the CYP2C19 gene in a rapid timeframe in emergency care settings at the point of care."

Big money involved previously from Glencore side:

Li-Cycle and Glencore Announce Global Strategic Partnership; Glencore to Make a $200 Million Investment in Li-Cycle

https://li-cycle.com/press-releases/li-cycle-and-glencore-announce-global-strategic-partnership-glencore-to-make-a-200-million-investment-in-li-cycle/

They invested some serious money in Li-Cycle earlier this year, not sure if we are potentially looking at a similar case here.

https://investors.li-cycle.com/news/news-details/2024/Li-Cycle-Announces-75-Million-Strategic-Investment-from-Glencore/default.aspx

What about July holiday season and offices being half empty?

Anyone attending today's exhibition in London?...

3,200,000 trade just popped up worth £60k

2x 1,000,000 trades at 1.7299 p reported £17.30k each

I am by no means a medical expert, but does anyone know what else needs to be proven?...

In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS. The decision was based on several differentiating features of the Genedrive® technology; (1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations, (2) no requirement for cold-chain storage logistics, (3) its ability to integrate with patient electronic healthcare systems.

Indeed, that could be their specific portfolio strategy which they would have to adhere to.

Definitely a lot of buying and selling going on today!...

Look at the trades.

At this pace they won't have any shares left by the end of the afternoon!

And it will be interesting to see how many views the Crux interview will have say in a week or month from now.

I wonder how many Australian investors are currently viewing from the sidelines ready to also jump onboard over the next few weeks after having seen yesterday's interview.

ogm

I just noticed the Crux interview released only yesterday mid day has already been viewed nearly 1300 times until now. Previously with past videos this number was a lot less after one day, so I reccon a good indicator showing growing interest in EEE attracting more and more attention recently.